3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Breast Neoplasms
2
Rhabdomyosarcoma
1
Retinoblastoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, AIDS-Related
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia
1
Infiltrating Bladder Urothelial Carcinoma
1
Hodgkin Disease
1
HER2-positive Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Blast Crisis
1
Amyloidosis
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
34
Specimen Handling
18
Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
Biopsy
14
Nivolumab
13
Ipilimumab
12
Gemcitabine
10
Irinotecan
9
Radiosurgery
8
atezolizumab
7
abemaciclib
7
Radiation
7
Pemetrexed
7
Cisplatin
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
trastuzumab deruxtecan
6
olaparib
6
durvalumab
6
avelumab
6
Docetaxel
6
osimertinib
5
adagrasib
5
Trastuzumab
5
Fulvestrant
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm Metastasis
×
pegfilgrastim
×
Clear all
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts